Ken Griffin Chinook Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $171,672 - $354,936	9,200 Added 204.44%	13,700 $526,000
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $36,601 - $45,560	-1,700 Reduced 27.42%	4,500 $104,000
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $4.73 Million - $6.95 Million	-254,000 Reduced 97.62%	6,200 $162,000
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $800,207 - $1.07 Million	-45,700 Reduced 14.94%	260,200 $5.12 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.